HLN:NYE-Haleon plc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 9.77

Change

+0.01 (+0.10)%

Market Cap

USD 43.99B

Volume

6.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.09 (+0.05%)

USD 85.62B
RDY Dr. Reddy’s Laboratories Ltd..

-59.38 (-80.25%)

USD 63.63B
TAK Takeda Pharmaceutical Co Ltd A..

+0.17 (+1.21%)

USD 44.45B
CTLT Catalent Inc

-0.21 (-0.36%)

USD 10.78B
ELAN Elanco Animal Health

+0.11 (+0.88%)

USD 6.18B
BHC Bausch Health Companies Inc

+0.43 (+4.64%)

USD 3.56B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.16 (-1.90%)

USD 2.55B
CPHI China Pharma Holdings Inc

-0.01 (-3.80%)

USD 4.03M
YCBD cbdMD Inc

-0.01 (-2.17%)

USD 2.11M
PBH Prestige Brand Holdings Inc

+0.98 (+1.33%)

N/A

ETFs Containing HLN

XS3R:LSE Xtrackers MSCI Europe Con.. 6.71 % 0.00 %

-19.00 (0.24%)

USD 0.06B
DXSK:XETRA Xtrackers - Stoxx Europe .. 6.71 % 0.00 %

+0.22 (+0.24%)

USD 0.07B
CUIK:XETRA Amundi MSCI UK IMI SRI PA.. 4.01 % 0.00 %

+0.01 (+0.24%)

USD 0.18B
UKSR:LSE UBS (Irl) ETF plc - MSCI .. 3.34 % 0.00 %

+5.80 (+0.24%)

USD 0.62B
UKSRE:SW UBS (Irl) ETF plc - MSCI .. 3.26 % 0.00 %

N/A

USD 0.09B
UKSR:SW UBS (Irl) ETF plc - MSCI .. 3.26 % 0.00 %

+0.12 (+0.24%)

USD 0.64B
UKSRT:SW UBS (Irl) ETF plc - MSCI .. 3.26 % 0.00 %

+0.02 (+0.24%)

USD 0.01B
ESIS:LSE iShares MSCI Europe Consu.. 3.23 % 0.00 %

-0.01 (0.24%)

USD 0.62B
STS:PA SSgA SPDR ETFs Europe II .. 3.08 % 0.00 %

-0.20 (0.24%)

USD 0.18B
STSX:SW SPDR® MSCI Europe Consum.. 3.08 % 0.00 %

+0.10 (+0.24%)

USD 0.19B
CSPE:LSE SPDR® MSCI Europe Consum.. 2.44 % 0.00 %

-0.34 (0.24%)

N/A
EXV4:XETRA iShares STOXX Europe 600 .. 2.00 % 0.00 %

-2.04 (0.24%)

USD 0.70B
SXDPEX:SW iShares STOXX Europe 600 .. 2.00 % 0.00 %

N/A

USD 0.44B
CSTP:LSE SPDR® MSCI Europe Consum.. 0.00 % 0.00 %

-0.40 (0.24%)

USD 0.19B
DXSK:F Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

+0.38 (+0.24%)

N/A
EXV4:F iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

N/A
SPYC:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

-0.15 (0.24%)

N/A
SPYC:XETRA SPDR® MSCI Europe Consum.. 0.00 % 0.00 %

-0.20 (0.24%)

USD 0.16B
FT1K:LSE Amundi MSCI UK IMI SRI PA.. 0.00 % 0.00 %

-0.70 (0.24%)

N/A
C1U:PA Amundi FTSE 100 UCITS 0.00 % 0.00 %

-3.10 (0.24%)

USD 0.04B
ESIS:F Ishares VI PLC - Ishares .. 0.00 % 0.00 %

N/A

USD 0.64B
ESIS:XETRA iShares MSCI Europe Consu.. 0.00 % 0.00 %

N/A

USD 0.58B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.71% 53% F 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.71% 53% F 75% C
Trailing 12 Months  
Capital Gain 20.77% 53% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.77% 53% F 62% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 7.95% 60% D- 62% D
Dividend Return 8.37% 53% F 57% F
Total Return 0.42% 20% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 12.75% 93% A 71% C-
Risk Adjusted Return 65.64% 93% A 81% B-
Market Capitalization 43.99B 70% C- 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector